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24 Dairy polar lipids (PL) seem to exhibit antiplatelet effects. However, it is not known what 
25 molecular species may be responsible. In this study, we confirmed using C30 reversed-phase 
26 (C30RP) ultra-high-performance liquid chromatography (UHPLC) coupled to high resolution 
27 accurate mass tandem mass spectrometry (HRAM-MS/MS) that fermentation of yoghurts from 
28 ovine milk using specific starter cultures altered the PL composition. These lipid alterations 
29 occurred concomitant with increased antithrombotic properties of the yoghurts PL fractions 
30 against platelet-activating factor (PAF) and thrombin-induced platelet aggregation. 
31 Specifically, elevation in phosphatidylethanolamine (PE), sphingomyelin (SM), 
32 phosphatidylcholine (PC) and their molecular species were observed following yoghurt 
33 fermentation. Furthermore, PC(18:0/18:1), PE(18:1/18:2), SM(d18:0/22:0) and several other 
34 molecular species were significantly inversely correlated with the inhibition of PAF and 
35 thrombin. These molecular species were abundant in the most bioactive yoghurts fermented by 
36 S. thermophilus and L. acidophilus, which suggest that fermentation by these microorganisms 











47 Cardiovascular diseases (CVD) are the leading cause of global mortality. Systemic 
48 inflammation is a key biochemical process implicated in the development of chronic diseases 
49 such as cancer  and CVD (Moss, Williams, & Ramji, 2018), whereby platelets are integral for 
50 the protection of the vascular system (Koupenova, Clancy, Corkrey, & Freedman, 2018). 
51 However, during unresolved systemic inflammation, activated platelets can induce a myriad of 
52 pro-inflammatory events that contribute to the initiation and progression of atherosclerosis 
53 (Koupenova, Clancy, Corkrey, & Freedman, 2018). Considering platelet hyperactivity and 
54 postprandial platelet activity areis a risk factors for CVD, (Mikellidi & Nomikos, 2016), it is 
55 imperative to develop therapeutic functional foods with antiplatelet properties. Platelet-
56 activating factor (PAF) is a potent phospholipid pro-inflammatory mediator implicated in the 
57 development of atherosclerosis (Tsoupras, Lordan, & Zabetakis, 2018). PAF and PAF-like 
58 lipids (PAFLL) are structurally homologous species that exhibit similar biological activity by 
59 binding to the PAF-receptor (PAF-R), which is a seven transmembrane G-protein-coupled 
60 receptor (GPCR). However, PAFLL tend to be less potent than PAF and or they can act as PAF 
61 inhibitors (Tsoupras, Lordan, & Zabetakis, 2018).
62 Fermented dairy products may be cardioprotective with respect to reducing CVD risks 
63 (Astrup, Geiker, & Magkos, 2019). YIndeed, yoghurt consumption is associated with the 
64 prevention of obesity, metabolic syndrome, type II diabetes mellitus, and CVD (Lordan, 
65 Tsoupras, Mitra, & Zabetakis, 2018; Wu & Sun, 2017). However, not all the cardioprotective 
66 mechanisms associated with dairy consumption are fully understood (Da Silva & Rudkowska, 
67 2015). Ovine milk and dairy products are a key component of the diet of populations 
68 surrounding the Mediterranean basin, regions around the Black Sea, the Indian subcontinent, 
69 and Africa, where they provide essential nutrients for people with low incomes. Ovine milk is 
70 a rich source of lipids that are thought to be bioactive by exerting anti-inflammatory and 
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71 antithrombotic effects (Megalemou, Sioriki, Lordan, Dermiki, Nasopoulou, & Zabetakis, 
72 2017), including the bioactive phospholipid and sphingolipid fractions collectively known as 
73 polar lipids (PL) (Lordan & Zabetakis, 2017). Milk polar lipids have been associated with 
74 several cardiovascular benefits (Anto, Warykas, Torres-Gonzalez, & Blesso, 2020; Millar, 
75 Jiang, Norris, Garcia, Seibel, Anto, et al., 2020). In humans, Mmilk PLs have been associated 
76 with a reduction of cardiovascular disease risk factors in overweight postmenopausal women 
77 (Vors, Joumard-Cubizolles, Lecomte, Combe, Ouchchane, Drai, et al., 2019). 
78 It was recently reported that various bacterial cultures can alter the fatty acid 
79 composition of PL in ovine milk when it was fermented to yoghurt, and that these changes led 
80 to an increase in the inhibitory effects of the PL against platelet-activating factor (PAF)-
81 induced platelet aggregation (Lordan, Walsh, Crispie, Finnegan, Cotter, & Zabetakis, 2019), 
82 which is a measure of the antithrombotic and potentially the anti-inflammatory effects of the 
83 PL. However, this study had several limitations as the main PL constituents responsible for the 
84 activity were not reported. Similar anti-PAF PL have been reported in cheeses produced from 
85 caprine milk fermented with different lactic acid bacteria (LAB) (Lordan, Walsh, Crispie, 
86 Finnegan, Demuru, Tsoupras, et al., 2019). Therefore, PL-rich ovine dairy products are putative 
87 candidates for the development of cardioprotective functional foods (Balthazar, Pimentel, 
88 Ferrão, Almada, Santillo, Albenzio, et al., 2017).
89 While these previous studies focused on the PAF pathways of platelets, it has recently 
90 been shown that PL also affect the thrombin pathways (Tsoupras, Lordan, Demuru, Shiels, 
91 Saha, Nasopoulou, et al., 2018). However, little is known about the effect of dairy PL on the 
92 activation of the thrombin platelet receptors (PAR-1 and PAR-4) or similar GPCR receptor like 
93 that of adenosine diphosphate (ADP) receptors P2Y1 and P2Y12. Therefore, the aim of this 
94 study is to determine the change of polar lipid composition after the fermentation of ovine milk 
95 to yoghurts produced using different starter cultures and to analyse their antiplatelet activity 
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96 against PAF, ADP, and thrombinthe aim of this study was to confirm previously reported data 
97 that demonstrated that fermentation increased the antiplatelet activity of PL against PAF-
98 induced platelet aggregation and to assess whether these trends existed for ADP and thrombin-
99 induced platelet aggregation. Finally, C30 reversed-phase (C30RP) ultra-high performance 
100 liquid chromatography (-UHPLC) coupled to high resolution accurate mass tandem mass 
101 spectrometry (-HRAM-MS/MS) (Pham, Zaeem, Fillier, Nadeem, Vidal, Manful, et al., 2019) 
102 and multivariate statistical analysis were used to determine the composition of the PL extracts 
103 of the ovine dairy products and to assess if there were structure/function relationships between 
104 the PL and their antithrombotic properties. Based on previously published research, it is 
105 hypothesised that there will be significant differences between the PL compositions of the milk 
106 and yoghurts, which will lead to differences in the antithrombotic properties of the PL extracts. 
107
108 2. Materials and methods
109 2.1. Materials & Chemicals
110 All consumables and HPLC-grade solvents: chloroform, methanol, and acetonitrile 
111 were obtained from Fisher Scientific Ltd. (Ottawa, ON, Canada). LC-MS-grade formic acid, 
112 acetic acid, and ammonium acetate were purchased from Sigma-Aldrich (ON, Canada). For 
113 solution preparation, deionised water (PURELAB Purification System, ELGA Labwater, ON, 
114 Canada) was used. Individual external lipid standards using SPLASH mix of deuterated 
115 standards were purchased from Avanti Polar Lipids Inc. (Alabaster, AL, USA), the 
116 composition of which is outlined in the supplementary material (Table S-2).  
117 The 20G safety needles and evacuated sodium citrate S-monovettes were purchased 
118 from Sarstedt Ltd. (Wexford, Ireland). The platelet aggregation bioassay was carried out on a 
119 Chronolog-490 two channel turbidimetric platelet aggregometer (Havertown, PA, USA), 
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120 coupled to the accompanying AGGRO/LINK software package. All platelet aggregation 
121 consumables were purchased from Labmedics LLP (Abingdon on Thames, UK). Standard 
122 thrombin, saline, and BSA were purchased from Sigma Aldrich (Wicklow, Ireland), while 
123 collagen and ADP were obtained from CHRONOLOG, Havertown, PA, USA. Centrifugations 
124 were carried out on an Eppendorf 5702R centrifuge (Eppendorf Ltd Stevenage UK). 
125 Spectrophotometric analysis was carried out on a Shimadzu UV-1800 spectrophotometer 
126 (Kyoto, Japan). The bacterial cultures used in this study were obtained in freeze dried form and 
127 turned into mother culture solutions as outlined in Table S-1 of the supplementary materials. 
128 The cultures were kindly provided by Chr. Hansen (Cork, Ireland).
129
130 2.2. Ovine milk and yoghurt polar lipid extracts. 
131 The PL extracts used in this study were obtained from a previously published study 
132 (Lordan, Walsh, Crispie, Finnegan, Cotter, & Zabetakis, 2019). In brief, whole milk was 
133 obtained from a bulk tank containing milk from the Friesland and Lacaune breed of dairy ewe 
134 between March and July in 2016. The sheep were fed a forage-based diet consisting of grass 
135 silage or fresh grass, supplemented with cereal at the time of milking at Rockfield Dairy Ltd. 
136 (Claremorris, Co. Mayo, Ireland). The milk was pasteurised at 91 °C for 15 s and was cooled 
137 to 42 °C before being homogenised, packaged, refrigerated at 4 °C, and transferred to the 
138 laboratory. The milk was placed in sterilised conical flasks and heated to 42 °C in a water bath 
139 (Grant JB NV, Cambridgeshire, UK) before specific concentrations of starter cultures were 
140 used to inoculate the milk as per (Table S-1 (supplementary material)). The flasks were held at 
141 42 °C throughout the yoghurt fermentation process. When inoculated the milk was stirred 
142 thoroughly and the pH monitored. The fermentation was stopped by cooling to 4 °C once the 
143 yoghurts reached a pH between 4.4 and 4.6. The yoghurts were transferred to sterile media 
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144 bottles and stored at -20 °C until required for analysis. The final microbial composition of the 
145 yoghurts as previously determined by Lordan, Walsh, Crispie, Finnegan, Cotter, and Zabetakis 
146 (2019) is presented in Table S-1. The milk, the control yoghurt (yoghurt A in this study), and 
147 the yoghurt deemed to be most bioactive in the previous study (yoghurt B in this study) were 
148 then extracted as previously describedusing the modified Bligh and Dyer method and the 
149 counter-current distribution as previously described (Lordan, Walsh, Crispie, Finnegan, Cotter, 
150 & Zabetakis, 2019). This method of polar lipid extraction is favoured over other methods as it 
151 does not require heat or harsh treatments that may affect the lipid structure or biological 
152 activities of the polar lipids. All lipid extracts were stored in the absence of any solvent under 
153 a nitrogen atmosphere in sealed vials at -20 °C. The mean extraction results and PL yields have 
154 previously been reported by Lordan, Walsh, Crispie, Finnegan, Cotter, and Zabetakis (2019). 
155
156 2.3. Analysis of polar lipid extracts using C30-RPLC-HRMS/MS
157 The milk and yoghurt PL extracts were analysed using C30 reversed-phase ultra-high 
158 performance liquid chromatography system coupled to high resolution mass spectrometry 
159 (C30RP-UHPLC-HRAM-MS/MS) in quadruplicate as previously described (Pham, Zaeem, 
160 Fillier, Nadeem, Vidal, Manful, et al., 2019). In brief, the C30RP-UHPLC was carried out using 
161 an Accucore C30 column (150 x 2 mm I.D., particle size: 2.6 µm, pore diameter 150 Å, 
162 (Thermo Fisher Scientific Ltd., ON, Canada). The mobile phase system comprised of solvent 
163 A (acetonitrile: water, 60:40 v/v) and solvent B (isopropanol: acetonitrile: water, 90:10:1 
164 v/v/v), which both contained 10 mM ammonium formate and 0.1% formic acid. The column 
165 oven temperature was set at 30 °C with a flow rate of 0.2 mL/min, and 5 µL of the lipid extract 
166 suspended in chloroform: methanol: isopropyl alcohol (2:2:1 v/v/v) was injected onto the 
167 column. The following system gradient was employed to separate the lipid classes and 
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168 molecular species:  30% solvent B for 3 min, 43% solvent B for 5 min, 50% solvent B for 1 
169 min, 90% solvent B for 9 min, then to 99% B for 8 min, and finally kept at 99% B for 4 min. 
170 The column was then re-equilibrated to starting conditions (70% solvent A) for 5 min prior to 
171 each new injection. 
172 The lipids were analysed using a Q-Exactive Orbitrap mass spectrometer controlled by 
173 X-Calibur software 4.0 (Thermo Fisher Scientific Ltd., MO, USA) with an automated Dionex 
174 UltiMate 3000 UHPLC system controlled by Chromeleon software. The Q-Exactive mass 
175 spectrometer was operated using the following conditions - sheath gas: 40, auxiliary gas: 2, ion 
176 spray voltage: 3.2 kV, capillary temperature: 300 °C; S-lens RF: 30 V; mass range: 200-2000 
177 m/z; full scan mode at a resolution of 70,000 m/z; automatic gain control target: le5. The 
178 instrument was externally calibrated to 1 ppm using ESI positive and negative calibration 
179 solutions (Thermo Fisher Scientific Ltd., MO, USA). Tuning parameters were optimised using 
180 a mixture of lipid standards obtained from Avanti Polar Lipids Inc. (AL, USA). Data was 
181 acquired and processed using X-Calibur 4.0. (ThermoScientific, MO, USA) and LipidSearch 
182 version 4.1 (Mitsui Knowledge Industry, Tokyo, Japan) software packages. LipidSearch was 
183 used for the identification and semi-quantification of the polar lipid classes and their molecular 
184 species. The LipidSearch parameters were as previously reported (Pham, et al., 2019). Briefly, 
185 there were as follows: Target database: Q-Exactive; precursor tolerance: 5 ppm; product 
186 tolerance: 5 ppm; product ion threshold: 5%; m-score threshold: 2; Quan m/z tolerance: ± 5 
187 ppm; Quan RT (retention time) range: ± 1  min; use of all isomer filter and ID quality filters 
188 A, B, and C; Adduct ions: [M+H]+ and [M+NH4]+ for positive ion mode, and [M-H]-, 
189 [M+HCOO]-, and [M-2H]2- for negative ion mode. Fatty acyl chains position identification 
190 present in the molecular species found in the lipid classes of each sample was based on the 
191 fragmentation patterns of the MS/MS spectra, and manually confirmed using X-Calibur 4.0. 
9
192 The relative amount of each molecular species identified was calculated from the normalised 
193 area counts and the values expressed as nanomole percent. 
194
195 2.4. Platelet aggregometry assay for ADP, PAF, and thrombin
196 Blood withdrawal and preparation of human platelet-rich plasma (hPRP) was 
197 conducted as previously described (Lordan, Walsh, Crispie, Finnegan, Cotter, & Zabetakis, 
198 2019; Tsoupras, Zabetakis, & Lordan, 2019). The study was approved by the Ethics Committee 
199 of the University of Limerick, which was performed in accordance with the Declaration of 
200 Helsinki. Healthy donors provided written consent and were free from any antiplatelet 
201 therapies. Briefly, blood samples were collected from six donors (n = 6) by a trained 
202 phlebotomist using sodium citrate anticoagulant (0.106 mol/L in a 1:10 ratio of citrate to blood; 
203 Sarstedt Ltd., Wexford, Ireland) and were centrifuged at 194 x g for 18 minutes at 24 °C with 
204 no brake applied. The supernatant hPRP was then transferred to polypropylene tubes at room 
205 temperature for the aggregation bioassays, whereas platelet-poor plasma (PPP) was obtained 
206 by further centrifuging the remainder of the blood at 1465 x g for 20 minutes at 24°C with no 
207 brake applied. hPRP was adjusted to 500,000 platelets/µL if required by addition of the 
208 respective volume of PPP according to the absorbance of the hPRP measured using 
209 spectrophotometer at 530 nm (Shimadzu UV-1800, Kyoto, Japan). The examined PL extracts 
210 were dissolved in BSA (2.5 mg BSA/mL saline) with standard stock solutions of PAF also 
211 being dissolved in BSA. Standard stock solutions of active thrombin (0.1 U/µL) and ADP (1 
212 mM) were dissolved in saline prior testing. 
213 The 250 µl of PRP was added to an aggregometer cuvette at 37°C with stirring at 1000 
214 rpm. The PRP was calibrated using the PPP as a blank. The maximum-reversible platelet 
215 aggregation curve induced by ADP, PAF, or thrombin was determined as 100% aggregation., 
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216 This was used as a baseline (0 % inhibition) value in the absence of any lipid-sample. This 
217 value was determined by adding the appropriate amounts of each platelet agonist toin the 
218 aggregometer cuvette, in order to reach specific final concentrations. These concentrations 
219 were; approximately 0.01-0.4 U/mL, for thrombin 2.6 x 10-10 to 2.6 x 10-12 M for PAF, and at 
220 2-10 μM for ADP.
221 The ADP-, PAF-, and thrombin-induced aggregation of hPRP was calculated first at 0 
222 % inhibition of baseline in a cuvette (100 % aggregation) in the absence of any lipid sample, 
223 whereas after the pre-incubation of hPRP with several amounts (μg) of the lipid samples in a 
224 different cuvette for 2 min, the same amount of ADP, PAF or thrombin that induced maximum-
225 reversible platelet aggregation was added and the reduced aggregation was calculated. Thus, a 
226 linear curve at the 20–80 % range of the percentage of inhibition against ADP-, PAF-, and 
227 thrombin-induced aggregation of hPRP was deduced for each sample. From this curve, the 
228 concentration (μg) of the lipid sample that led to 50% of agonist-induced aggregation of hPRP 
229 was calculated as the 50 % inhibitory concentration value also known as the IC50 value (half-
230 maximal inhibitory concentration) for each PL sample. The resulting IC50 values were 
231 expressed as a mean value of the mass of lipid (µg) in the aggregometer cuvette ± standard 
232 deviation (SD). All experiments were performed in sextuplicate (n = 6) using a different donors 
233 blood sample for each replicate to ensure reproducibility.
234
235 2.5. Statistical Analysis
236 The Kruskal-Wallis test was used to determine significant statistical differences 
237 between the extracts tested in the aggregometry experiments (XLSTAT, Premium, version 
238 2019.3.1, Addinsoft, New York, USA). Statistical analysis of the lipidomic data was carried 
239 out using XLSTAT, whereby principal component analysis (PCA), heatmaps, and bar charts 
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240 depicting relative abundance of each PL species and the ANOVA were plotted using variable 
241 importance of projection (VIP) >1 following partial least square discriminant analysis (PLS-
242 DA). ANOVA was conducted using Fisher’s least significant difference (LSD) posthoc test (p 
243 < 0.05 was deemed statistically significant) to assess the differences in the lipidomic profiles 
244 of the milk and yoghurts. All heatmaps were conducted using a hierarchical clustering based 
245 on Euclidian distance at 0.15 interquartile range. PCA and Pearson correlation coefficients 
246 were used to discern if the biological activity correlated with the PL species present (XLSTAT). 
247 Chemical structures were generated using ChemDraw (Ultra 7.0, PerkinElmer Inc., Waltham, 
248 MA, USA), chromatograms by X-Calibur software 4.0 (Thermo Fisher Scientific Ltd., MO, 
249 USA), and Fig. 5 was generated using BioRender (Toronto, ON, Canada).
250
251 3. Results and Discussion
252 3.1. Composition of the ovine milk and yoghurt polar lipids
253 Fermentation significantly affected the overall fatty acid composition of milk (Vieira, 
254 Álvares, Gomes, Torres, Paschoalin, & Conte-Junior, 2015). It was previously reported using 
255 GC-MS that fermentation of ovine milk using specific starter cultures also altered the fatty acid 
256 composition of PL (Lordan, Walsh, Crispie, Finnegan, Cotter, & Zabetakis, 2019). However, 
257 this approach was limited in what could be deduced in relation to the PL groups present in these 
258 extracts and how fermentation may alter their structure and biological activity. We 
259 hypothesised that there would be significant changes to the milk phospholipidome following 
260 fermentation to yoghurt. Using C30RP-UHPLC-HRAM-MS/MS it is now confirmed that the 
261 PL composition of the sheep milk when fermented to yoghurt did significantly alter the overall 
262 PL composition and the molecular species of the various PL groups, namely 
263 phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylglycerol (PG), 
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264 phosphatidylserine (PS), phosphatidylinositol (PI,)  and sphingomyelin (SSM). This is in 
265 accordance with recently published research concerning bovine milk, yoghurt, and cheese 
266 (Furse, Torres, & Koulman, 2019). An example of a chromatogram obtained using C30-RPLC-
267 HRMS/MS in the negative ion mode is presented in Fig. 1A. Fig. 1B-D are representative mass 
268 spectra of some of the main PL species identified in the milk and yoghurt extracts. The base 
269 peaks of fatty acids were typically generated from glycerophospholipids confirming their fatty 
270 acyl composition, e.g. m/z 281.24 and 283.26 in Fig. 1B,C representing C18:1 and C18:0 fatty 
271 acyl anion produced from PC(18:0/18:1), PE(18:0/18:1), respectively. The base peak of m/z 
272 168.04 in Fig. 1D was distinguishable for the phosphocholine polar headgroup and the presence 
273 of sphingosine backbone in SM(d16:0/18:1). The analysis determined that PE (46-52%) was 
274 the most abundant PL fraction detected in the milk and yoghurts, followed by SM (19-26%), 
275 PC (16-17%), PS (10-12%), PI (~ 1%), and PG (<1%) (Fig. 1E). While the SM and PS 
276 composition of the ovine milk was generally in accordance with the literature, the relative 
277 abundance of PE and PC was found to be higher in the milk used in this study in comparison 
278 to the literature (Zancada, Pérez-Díez, Sánchez-Juanes, Alonso, García-Pardo, & Hueso, 
279 2013). These differences may be due to multiple reasons such as the time of year the milk was 
280 taken, the stage of lactation, the breed of the sheep, and their diets; all of which tend to have a 
281 significant impact on the composition of the milk of various ruminant animals (Balthazar, et 
282 al., 2017). It is clear from Fig. 1E that there are differences in the total relative percentage of 
283 the PL groups between the milk and yoghurts and within the yoghurts themselves, indicating 
284 that the fermentation of milk to yoghurt and the starter cultures used considerably altered the 
285 PL composition.; which could lead to a changes in the bioactivity of the fermented products. 
286 Notably, PE was significantly higher (p < 0.05) in the ovine milk than in yoghurt A. Juxtaposed, 
287 the percentage of SM tends to significantly increase in the yoghurts, whereas a 1% percent 
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288 increase in the relative abundance of PC was observed as a function of the different starter 
289 cultures used during fermentation.  
290 *Insert Fig. 1. Here* 
291 *Insert Fig. 2. Here* 
292 To determine whether there were differences in the PL subclasses at the fatty acyl 
293 chains level, the molecular species of each PL class were also evaluated. As aforementioned, 
294 PE was the most abundant PL detected in the milk and yoghurts. The heatmap in Fig. 2A., 
295 demonstrates that the molecular species of the yoghurt PE cluster together, but separately from 
296 the milk PE, indicating that the yoghurt PE species are different from the ovine milk PE species. 
297 This demonstrates that fermentation alters the composition of the PE molecular species. The 
298 heatmap clusters the PE molecular species into two general groups, G1 and G2, which 
299 distinguish the milk from the yoghurt PE molecular species. In particular, there is a statistically 
300 significant higher level of ether linked PE molecular species (G1), where the relative abundance 
301 (nmol%) of PE(16:1e/18:1), PE(16:1e/19:1), PE(18:1e/18:1), PE(16:1e/22:5), and 
302 PE(18:2e/18:1) are significantly higher (p < 0.05) in the milk than yoghurts A or B. The 
303 heatmap (G2) also shows that there is a higher concentration of unsaturated PE species that 
304 lacking an ether bond in the yoghurts in contrast to the milk., In particularly PE(17:0/18:1) and 
305 PE(18:1/18:2) are in higher abundance in the yoghurts. This is corroborated by Fig. 2B., that 
306 shows that there is a statistically significant difference in the concentration of these PE species 
307 between the milk and yoghurts. There are also subtle differences in the concentration of certain 
308 PE molecular species as demonstrated by the clustering of the two yoghurts separately from 
309 each other as denoted by subgroup 1 and 2 (SG1 and SG2) in Fig. 2B. Thus, fermentation 
310 specifically alters the content of PE molecular species, particularly by significantly reducing 
311 the relative abundance of PE species with ether bonds.
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312 SM was the second most abundant PL detected in the milk and yoghurt TPL extracts 
313 (19-26%). The heat map in Fig. 2C. demonstrates that yoghurt B segregated from yoghurt A 
314 and the milk, which also clusters independently from each as indicated by the hierarchical 
315 clustering based on a Euclidian distance set at an interquartile range of 0.15. In particular, 
316 yoghurt B is separated from the milk and yoghurt A by a higher relative abundance of SM 
317 species that generally consist of a carbon chain length of 40 carbons or lower and generally 
318 contain 1 double bond. Indeed, yoghurt B had a statistically significantly higher concentration 
319 of SM(d16:0/18:1) and SM(d19:0/20:1) as confirmed in Fig. 2D. Conversely, the milk and 
320 yoghurt A share a statistically significantly (p < 0.05) higher abundance of SM(d18:1/24:1). In 
321 addition, yoghurt A is separated from the milk and yoghurt B by a statistically significantly 
322 higher abundance (p < 0.05) of SM(d20:1/23:0) as depicted in Fig. 2C and 2D. Indeed, the 
323 yoghurts are also segregated by a lower relative abundance of SM(d20:1/23:1) in yoghurt B in 
324 contrast to yoghurt A and the milk. 
325 The relative abundance of PC in the milk and yoghurts was between 16-17% of the total 
326 PL composition, making it the third most prominent group of PL. The PC heat map (Fig. 2E) 
327 indicates that the yoghurts clustered together, but separately from the milk by higher 
328 concentration of unsaturated PC molecular species (G1), particularly PC(17:0/18:2), 
329 PC(18:0/16:0), PC(18:1/18:2), and PC(18:0/18:1). Conversely, the milk segregates distinctly 
330 from the yoghurts by having a significantly (p < 0.05) higher abundance of saturated PC species 
331 (G2), including PC(12:0/14:0), PC(16:0/12:0), and PC(16:0/14:0). Yoghurt A and B are also 
332 mainly segregated from each other due to a significantly higher concentration of saturated 
333 PC(16:0/16:0) and PC(15:0/16:0) molecular species in yoghurt A, and a higher concentration 
334 of PC(18:0/16:0) in yoghurt B (Fig. 2E and 2F) amongst other species. In contrast to the 
335 composition of the PE, there were no ether lipids detected in either the milk or yoghurt PC 
336 molecular species.
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337 *Insert Fig. 3. Here* 
338 PS was the fourth most abundant PL detected in the milk and yoghurt TPL extracts (10-
339 12%). The PS heatmap (Fig. 3A.) demonstrates that the milk and yoghurts differ from each 
340 other based on two groups of PS species. G1 demonstrates that yoghurt B is significantly 
341 different from the milk by the higher relative abundance of PS(18:0/21:0) and PS(18:1/21:0), 
342 where yoghurt A is different from the milk only by the higher relative abundance of 
343 PS(18:0/21:0)  (Fig. 3A - 3B). On the other hand, G2 demonstrates that milk and yoghurt A 
344 has a statistically significantly higher relative abundance of PS(18:0/18:1), PS(18:0/22:5), 
345 PS(18:1/18:1), and PS(18:1/18:2) in contrast to yoghurt B. Therefore, it is clear that yoghurt B 
346 has a significantly different PS composition in contrast to the milk or yoghurt A. 
347 The relative abundance of PI in the milk and yoghurts was 1-3%, while this is 
348 considerably low, it is clear from the heat map that the milk and yoghurts segregates 
349 independently from each other (Fig. 3C). In general, the PI molecular species were broadly 
350 distinguished  by G1 and G2. The PI species in G2 are present in abundance in the milk, in less 
351 abundance in yoghurt A, and in low abundance in yoghurt B. In particular, the relative 
352 abundance of PI(18:1/18:1) and PI(16:0/18:1) is statistically significantly higher in the milk 
353 and yoghurt A, than yoghurt B (Fig 3C - 3D). However, in G1, PI(18:1/18:2) is in significantly 
354 higher abundance in yoghurt B in contrast to yoghurt A and the milk.      
355 Overall, it is clear that fermentation significantly alters not only the TPL profile, but 
356 the overall composition of PE, SM, PC, PS, and PI in the milk and yoghurts. Furthermore, there 
357 were statistically significant differences in the fatty acyl composition in each of the various PL 
358 species, which led to two significantly different yoghurt PL profiles following ovine milk 
359 fermentation.   
360
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361 3.2. Antiplatelet effects of ovine milk and yoghurt polar lipids
362 One question we wanted to address is whether the altered PL profiles observed 
363 following fermentation could potentially confer any health benefits in reducing CVD risks 
364 considering the proposed roles of dairy products and milk PL in improving cardiovascular 
365 health (Lordan, Tsoupras, Mitra, & Zabetakis, 2018; Vors, et al., 2019). As such, tThe milk 
366 and yoghurt TPL extracts were assessed against ADP, PAF, or thrombin-induced platelet 
367 aggregation and the results are presented in Table 1. Results are expressed as IC50 values of the 
368 mean mass of PL (µg) ± standard deviation (SD). Previously it was demonstrated that these 
369 extracts exhibited anti-PAF activity against human platelet aggregation (Lordan, Walsh, 
370 Crispie, Finnegan, Cotter, & Zabetakis, 2019). In this study, these aggregometry tests were 
371 replicated in six different human blood samples and the results against PAF were in accordance 
372 with the previously published data (Lordan, Walsh, Crispie, Finnegan, Cotter, & Zabetakis, 
373 2019). However, the anti-ADP or anti-thrombin effect of dairy PL extracts have were not been 
374 previously assessed. The results of this study indicate that ovine milk and yoghurts exhibit 
375 potent anti-thrombin activity. Yoghurt A (33.7 ± 6.4) had a lower IC50 than the ovine milk 
376 (37.5 ± 5.2). However, this was not significantly different (p > 0.05). In contrast, yoghurt B 
377 had an IC50 (14.7 ± 6.0) that was significantly (p < 0.05) lower than the milk and yoghurt A. 
378 These anti-thrombin effects were more potent than those previously published for salmon PL 
379 characterised by several diacyl-PC/PE and alkyl-acyl-PC/PE species bearing mostly 
380 eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) at the sn-2 position of the 
381 glycerol backbone (Tsoupras, et al., 2018; Tsoupras, Lordan, Shiels, Saha, Nasopoulou, & 
382 Zabetakis, 2019). This is important as these are ω3 fatty acids that are purported to exhibit 
383 antithrombotic activity. However, as our study indicates, PL extracts low in ω3 fatty acid 
384 content may be just as antithrombotic as those that are characterised as PL with a high ω3 fatty 
385 acid content. 
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386 Juxtaposed, the anti-ADP effects of these milk and yoghurt PL extracts were not as 
387 potent as thrombin or PAF, but still appreciable. Neither the milk nor yoghurt IC50 values were 
388 significantly different from each other, indicating that fermentation to yoghurt did not seem to 
389 impact the anti-ADP activities of these extracts. Previous research shows that a pilot crossover 
390 intervention study of 10 participants that consumed 200 g/wk of pecorino cheese (made with 
391 ovine milk) enriched in conjugated linoleic acid (CLA) cis-9, trans-11, did not significantly 
392 reduce ADP-induced platelet aggregation (Sofi, Buccioni, Cesari, Gori, Minieri, Mannini, et 
393 al., 2010). Although that study did have its limitations, there was a significant reduction of 
394 arachidonic acid-induced platelet aggregation, indicating that dairy foods can certainly affect 
395 platelet reactivity. Therefore, further research is warranted to discern whether other dairy PL 
396 extracts can affect ADP or indeed arachidonic acid-induced platelet aggregation.
397 *Insert Table 1 Here*
398
399 3.3. Milk and yoghurt polar lipid structures affect biological activity
400 Although dairy product consumption seems to be associated with beneficial 
401 cardiovascular health , the mechanisms responsible for these observed benefits have yet to be 
402 fully elucidated. However, it is postulated that dietary PL  including dairy-derived PL (Lordan, 
403 Walsh, Crispie, Finnegan, Cotter, & Zabetakis, 2019), may exert anti-inflammatory and 
404 antithrombotic effects upon consumption. However, there are limited human studies to confirm 
405 whether dairy product consumption affects platelet homeostasis; although there are promising 
406 indications that it may (Sofi, et al., 2010). It was hypothesised that changes in the PL 
407 composition due to fermentation may lead to changes in the antithrombotic properties of the 
408 ovine milk PL. Fig. 4 shows the PCA biplots of the relative abundance of the overall (Fig. 4A) 
409 and individual (Fig. 4B-F) PL species with a variable importance of projection (VIP) >1 
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410 following PLS-DA plotted with the antithrombotic data. In accordance with the previous 
411 results,  discussed in section 3.1, the milk and yoghurts are distinct from each other due to their 
412 PL composition. It was observed that the SM, PC, and PA classes in yoghurt B clustered 
413 together with the thrombin and PAF antiplatelet activity (see Fig. 4A). This suggests a possible 
414 relationship between these PL classes and the superior antithrombotic properties detected in 
415 yoghurt B PL extracts (Table 1). as previously suggested for PC and SM in marine PL extracts 
416 (Tsoupras, Lordan, Shiels, Saha, Nasopoulou, & Zabetakis, 2019).  The milk clustered 
417 predominantly into quadrant 1 due to the PE and PI classes and yoghurt A segregated into 
418 quadrant 2 due to its PG and PS classes. These groupings accounted for 55.52% of the total 
419 variance present in the data. Yoghurt B exhibited the most potent antiplatelet effects against 
420 these agonists and the SM class was inversely correlated with both thrombin and PAF-induced 
421 platelet aggregation (Fig. 4A and Table S-3). This indicates that the changes in the milk and 
422 yoghurt PL profiles can lead to more favourable antithrombotic properties. 
423 *Insert Fig. 4 Here*
424 Furthermore, the observed PL molecular species that clustered with the thrombin and 
425 PAF antiplatelet activity in the milk and yoghurt samples were then evaluated to determine if 
426 there were any significant associations between these parameters. The biplot of Fig.4B presents 
427 the PCA of the PE molecular species of the milk and yoghurts and their biological activity. The 
428 milk samples are clustered in the positive quadrant and the yoghurts are clustered on the 
429 negative quadrants of the first component respectively, whereby these grouping account for 
430 67.03% of the total variance in the data set. This can mainly be attributed to the higher relative 
431 abundance of ether lipids in the milk in contrast to their lower abundance in the yoghurts, as 
432 observed in the heatmap of the PE molecular species in section 3.1. Moreover, yoghurt A and 
433 yoghurt B are divided based on the PE molecular species in component 2 of the PCA. PE 
434 molecular species were associated with inhibition of PAF and thrombin. In particular, 
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435 PE(17:0/18:1), PE(18:0/18:0), and PE(18:0/18:1) were significantly but inversely correlated 
436 with anti-PAF effects, whereas PE(18:1/18:2) was inversely correlated with the inhibition of 
437 both PAF and thrombin (Table S-3). Notably, PE(18:0/18:0) has previously been identified as 
438 a main constituent of potent anti-PAF PL extracts of gilthead sea bream (Sioriki, Smith, 
439 Demopoulos, & Zabetakis, 2016). Indeed, as observed in the ovine yoghurts, most of the PE 
440 species in these fish PL contained either 18:0 or 18:1 at the sn-1 position, which may be a 
441 contributory factor in the biological activity of PE species. Previous research indicates that 
442 isolated PE extracts of ovine and caprine dairy products inhibited PAF-induced platelet 
443 aggregation (Megalemou, Sioriki, Lordan, Dermiki, Nasopoulou, & Zabetakis, 2017), thus 
444 indicating that the PE fraction of ovine milk has the potential to inhibit PAF-related biological 
445 activity. 
446 The SM biplot (Fig. 4C.) clustered the milk and the yoghurt PL in components 1, 3, and 
447 4 of the biplot and this grouping accounted for 73.03% of the total variance present in the data. 
448 Yoghurt B mainly clusters into quadrant 1 and was correlated with the PAF and thrombin 
449 inhibition. The SM molecular species SM(d18:1/18:1), SM(d16:0/18:1), and SM(d18:0/22:0) 
450 were all significantly inversely correlated with thrombin inhibition, whereas the latter SM 
451 species was also significantly inversely correlated with PAF inhibition (Table S-3). 
452 Sphingolipids are integral to platelet activation, particularly in relation to thrombin, 
453 which causes platelets to release sphingosine-1-phosphate and increase levels of sphingosine, 
454 thus potentiating platelet aggregation (Simon & Gear, 1999). As such, sphingolipids are 
455 considered bioactive regulators of thrombin generation, whereby sphingosine, sphinganine, 
456 glucosylsphingosine, lysosphingomyelin, and similarly structured sphingolipids, but not 
457 ceramide or sphingosine-1-phosphate, which down-regulate thrombin generation (Deguchi, 
458 Yegneswaran, & Griffin, 2004). However, sphingolipids have a complex relationship with 
459 human cardiovascular health, whereby some endogenous sphingolipid metabolites are 
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460 associated with a pro-inflammatory role in atherosclerosis and others an anti-inflammatory role 
461 (Edsfeldt, Dunér, Ståhlman, Mollet, Asciutto, Grufman, et al., 2016; Lordan & Zabetakis, 
462 2017). However, dietary sphingolipids seem to influence inflammation-related chronic 
463 diseases through the activation of anti-inflammatory nuclear receptors, neutralizing responses 
464 to inflammatory stimuli, inhibiting intestinal lipid absorption, and altering gut microbiota . 
465 Previous studies suggest that the SM fraction of bovine, caprine, and ovine dairy products seem 
466 to exhibit PAF inhibitory or weakly agonistic effects that are several order of magnitude less 
467 potent than PAF (Megalemou, Sioriki, Lordan, Dermiki, Nasopoulou, & Zabetakis, 2017; 
468 Tsorotioti, Nasopoulou, Detopoulou, Sioriki, Demopoulos, & Zabetakis, 2014). However, the 
469 structures involved in these biological effects were never previously elucidatedpublished. 
470 In this study, we report that the total sum of SM species, and several individual 
471 molecular species of SM, especially SM(d18:0/22:0) and SM(d18:1/22:0), were strongly 
472 inversely correlated with the inhibition of both PAF and thrombin (Table S-3). This is in 
473 accordance with previous research assessing PL of marine (Tsoupras, et al., 2018; Tsoupras, 
474 Lordan, Shiels, Saha, Nasopoulou, & Zabetakis, 2019) and dairy (Megalemou, Sioriki, Lordan, 
475 Dermiki, Nasopoulou, & Zabetakis, 2017; Tsorotioti, Nasopoulou, Detopoulou, Sioriki, 
476 Demopoulos, & Zabetakis, 2014) PL extracts. It is essential to further research the SM fraction 
477 of dairy products and particularly these ovine milk and yoghurts, as they are a rich natural 
478 source of bioactive SM that have the potential to be utilised and altered for the production of 
479 functional foods and nutraceuticals capable of affecting platelet function and inflammatory 
480 pathways. 
481 While the relative abundance of the PC species did not seem to differ significantly 
482 between the milk and yoghurts (Fig. 1E), a clear separation of the milk and yoghurt PC 
483 molecular species was evident in this study (Fig. 4D). Furthermore, PAF and thrombin 
484 activities were clustered in quadrant 3 with yoghurt B derived PC molecular species (total 
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485 variance 74.92%). In particular, PC(18:0/16:0) and PC(18:0/18:1) were inversely correlated 
486 with PAF and thrombin inhibition, whereas PC(17:0/18:2) was inversely correlated with only 
487 PAF inhibition. The PC fraction of various yoghurts anddairy and marine salmon sources have 
488 previously exhibited PAF inhibitory effects (Megalemou, Sioriki, Lordan, Dermiki, 
489 Nasopoulou, & Zabetakis, 2017; Sioriki, Smith, Demopoulos, & Zabetakis, 2016; Tsoupras, et 
490 al., 2018). Furthermore, several PC species were previously reported in an anti-PAF PL extract 
491 of marine origin (Sioriki, Smith, Demopoulos, & Zabetakis, 2016). However, their fatty acid 
492 compositions were not reported. and salmon PC has also exhibitedIndeed, studies on the PC 
493 fractions of salmon PL using food-grade and non-food-grade extraction techniques 
494 demonstrate that PC inhibits PAF and anti-thrombin effectthrombin-induced platelet 
495 aggregation (Tsoupras, et al., 2018; Tsoupras, Lordan, Shiels, Saha, Nasopoulou, & Zabetakis, 
496 2019). Notably, the PC species in the goat and sheep meat fractions and the salmon PC fractions 
497 appear to be very dissimilar to those of the bioactive yoghurts evaluated in this study (Poutzalis, 
498 Lordan, Nasopoulou, & Zabetakis, 2018; Tsoupras, et al., 2018). These fractions are 
499 characterised by higher levels of ω3 fatty acids versus the PL of yoghurts. This demonstrates 
500 that PC fractions that do not contain PUFA can exhibit antiplatelet activities.   
501 Finally, the antithrombotic activities of PS and PI fractions of dairy products have not 
502 previously been assessed due to their low relative abundance, thus it was not known whether 
503 these species contribute to the antiplatelet effects of PL extracts. However, in this study, PS 
504 accounts for 10-12% and PI accounts for approximately 1% of the relative abundance of the 
505 total PL of the milk and yoghurts. Notably, some species of PS and PI were inversely correlated 
506 with the observed antiplatelet effects of the milk and yoghurts namely PS(18:0/21:0), 
507 PS(18:1/21:0), and PI(18:1/18:2) (Fig. 4E-F; Table S-3). Mechanistically, many PS and PI 
508 species are integral to proper platelet function. In terms of PS, in an activated state, the platelet 
509 plasma membrane surface gradually exposes aminophospholipids through translocation via 
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510 ATP dependent scramblases and flippases to trigger the coagulation cascades. The 
511 externalisation of PS and PE is a crucial process necessary for effective inflammation related 
512 platelet activation in both acute and resolving stages (Ghoshal & Bhattacharyya, 2014). 
513 Similarly, PI species are major signalling molecules in platelet function (O'Donnell, Murphy, 
514 & Watson, 2014). It is known that dietary lipids, such as the intake of polyunsaturated fatty 
515 acids (PUFA) obtained from food or supplementation, can alter platelet lipid composition and 
516 function (Walker, West, Browning, Madden, Gambell, Jebb, et al., 2015). However, it is not 
517 known exactly how dietary PL may affect these pathways, thus further research is warranted.
518
519
520 3.4. Potential antiplatelet mechanisms of milk and yoghurt polar lipids 
521 The mechanisms by which dietary PL seem to exert their biological influences against 
522 the PAF and thrombin pathways are complex and in the case of thrombin not fully elucidated. 
523 Fig. 5 is a schematic illustration of some of the potential modes of action of dietary PL, 
524 detailing their possible effect on the PAF and thrombin receptors and the surrounding platelet 
525 membrane. For example, Fig. 5A is a heat map of the PL species observed in this study that 
526 were highly correlated with antiplatelet activity against PAF and thrombin. Again, it is clear 
527 from the heat map that there is a higher concentration of the bioactive PL clustering with 
528 yoghurt B (S1). In contrast, the ovine milk and yoghurt A do cluster separately from each other 
529 but are more similar to each other than to yoghurt B (S2). The PL molecular species that highly 
530 correlated with the PAF activities are potential structural ligands of the PAF-R as they are 
531 structurally homologous to PAF (Lordan, Tsoupras, & Zabetakis, 2017), which indicates that 
532 there mode of action may be through competitive binding of the PAF-R. Notably, the majority 
533 of the PL molecular species that are present in higher relative abundances in yoghurt B tend to 
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534 be PC, PE, and SM species, which have also previously exhibited antiplatelet activity . In 
535 previnious studies of marine extracts, these PL classes exhibited potent inhibition of PAF and 
536 thrombin induced platelet aggregation (Tsoupras, et al., 2018). 
537 As per Table S-3, there seems to be a general trend that indicates that the dairy PL 
538 molecular species that are highly correlated to the antiplatelet effects of dairy PL against PAF 
539 and thrombin are characterised by either stearic acid (18:0) or oleic (18:1) at the sn-1 position 
540 such as PE(18:0/18:1), PE(18:1/18:2), and PC(18:0/18:1). This may be a significant structural 
541 feature that dictates whether PL are potent PAF antagonists or not considering that naturally 
542 occurring PAF from rabbit basophils are reported to contain either stearic acid (~ 90%) or 
543 palmitic acid (~ 10%) at the sn-1 position (Hanahan, Demopoulos, Liehr, & Pinckard, 1980). 
544 Additionally, oleic acid as a free fatty acid has exhibited inhibition of PAF signal transduction 
545 in platelets by decreasing polyphosphoinositide metabolism, which is critical to platelet 
546 activation (Nunez, Randon, Gandhi, Siafaka-Kapadai, Olson, & Hanahan, 1990). Whether a 
547 phospholipid bearing oleic acid can affect these same signalling pathways remains to be 
548 determined. Likewise, other fatty acyl groups that are associated with platelet reactivity such 
549 as DHA (22:6), arachidonic acid (20:4), and palmitic acid were identified on the sn-2 position 
550 of some PL molecular species, the latter bring a structural component of the classic PAF 
551 molecule. Further research is warranted to distinguish to what extent these PL molecular 
552 species affect PAF and thrombin induced platelet aggregation in humans.  
553 Fig. 5 B1 and B2 demonstrates how dairy PL and the structures observed in this study 
554 may competitively bind with the PAF-R, thus inhibiting the effects of PAF and PAFLL 
555 preventing downstream signalling events. Dairy PL molecular species may inhibit Gq-linked 
556 mechanisms whereby phosphatidylinositol 4,5-bisphosphate (PIP2) hydrolysis is mediated by 
557 phospholipase C beta (PLCβ) to produce inositol triphosphate (IP3) and diacylglycerols (DAG) 
558 that leads to a transient elevation of cytosolic Ca2+ and activation of protein kinase C (PKC). 
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559 Elevated Ca2+ activates cytosolic phospholipase A2α (cPLA2α) that leads to a release of 
560 lysophosphatides and arachidonic acid that act as substrates for the synthesis of eicosanoids 
561 and PAF respectively, which amplifies the platelet response. Inhibition of these pathways 
562 would prevent platelet aggregation and inflammatory signalling. Juxtaposed, dairy PL may also 
563 affect signalling through Gi-linked mechanisms , which inhibit the conversion of adenosine 
564 triphosphate (ATP) to adenosine 3′,5′-cyclic monophosphate (cAMP) by adenylate cyclase, 
565 thus preventing the activation of protein kinase A (PKA) and related anti-inflammatory 
566 signalling events (Tsoupras, Lordan, & Zabetakis, 2018). However, further research is required 
567 to discern how these mechanisms are affected by dairy PL. 
568 While there is a wealth of evidence indicating that dietary PL directly act on the PAF-
569 R (Lordan, Tsoupras, & Zabetakis, 2017) due to their structural similarities with PAF,  
570 including a hydrophilic head group, a glycerol backbone, and a fatty acyl group at the sn-1 
571 position (Fig 5C), the mechanisms by which dietary PL affect thrombin or even ADP activation 
572 is not known. However, it is thought that PL may indirectly affect platelet GPCRs by altering 
573 the microenvironment and polarisation of the phospholipid membrane, which potentially alters 
574 the affinity of respective platelet agonists to their receptor relating to platelet activation as 
575 demonstrated in B3 and B4 (Lordan, Tsoupras, & Zabetakis, 2017; Yoshida, Nagatoishi, 
576 Kuroda, Suzuki, Murata, & Tsumoto, 2019). Notably, platelet receptors for ADP, PAF, and 
577 thrombin are all GPCRs, indicating that this may be the common feature that explains the 
578 antiplatelet effects of the dairy PL. However, while ADP was inhibited by the PL extracts, it 
579 seems that fermentation and the subsequent change in the PL composition did not significantly 
580 affect ADP inhibition by the PL, in contrast to PAF or thrombin. Further research is required 
581 to understand how dairy PL may affect ADP-induced platelet aggregation.
582 *Insert Fig. 5 Here*
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583 Generally, there is a paucity of literature assessing the antithrombotic effects of milk 
584 and dairy consumption including the PL and LAB lipid metabolites in dairy products. In the 
585 previous assessment of these ovine milk and yoghurt PL extracts it was determined that 
586 yoghurts that contained a higher level of S. thermophilus and L. acidophilus in the initial starter 
587 culture and in the final yoghurt product (yoghurt B in this study) possessed greater bioactivity 
588 against PAF. Furthermore, soluble factors released by L. acidophilus in particular have 
589 exhibited anti-inflammatory effects against PAF by affecting signalling pathways such as the 
590 nuclear factor kappa B (NF-κB), and the mitogen activated protein kinase (MAPK) signalling 
591 pathways in vitro and in vivo (Borthakur, Bhattacharyya, Kumar, Anbazhagan, Tobacman, & 
592 Dudeja, 2013). 
593 This study demonstrates that fermentation of ovine milk by L. acidophilus and S. 
594 thermophilus changes the milk PL composition leading to greater antithrombotic properties. 
595 The is due to the anabolic and catabolicmetabolic capacity of these starter cultures 
596 usedmicroorganisms as demonstrated by the metagenomic analysis previously assessed 
597 (Lordan, Walsh, Crispie, Finnegan, Cotter, & Zabetakis, 2019). However, further research is 
598 required to discern the exact metabolic pathways directly responsible for altering the PL 
599 content of milk in order to utilise these pathways for the production of tailored functional 
600 cardioprotective foods.  
601
602 3.5. Study limitations 
603
604 This current study has its limitations in what can be concluded with regards to potential 
605 in vivo platelet function. However, , but generally light transmission aggregometry is 
606 considered the gold standard of platelet function testing as it reflects in vivo platelet 
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607 aggregation (McEwen, 2014). It is important to test the effect of these PL against other platelet 
608 agonists such as arachidonic acid and collagen in future human studies and in humans and 
609 using alternative methodologies to assess their antiplatelet effects, such as studies relating to 
610 analysing direct thrombus formation in vivo. Indeed, this study is also limited by its assessment 
611 of intact PL. The majority of PL consumed are digested by phospholipase A2, which cleaves 
612 the ester bond at the sn-2 position leading to the release of the lyso-form of the PL and free 
613 fatty acids. These digestive products are then absorbed by enterocytes in the gastrointestinal 
614 tract, which are then transported to the lymphatic system and subsequently the circulatory 
615 system as chylomicrons, whereby they are eventually resynthesised into phospholipids or 
616 triacylglycerols (Dixon, 2010). WNotably, within 5-6 h of ingestion, some PL are transferred 
617 directly into high-density lipoproteins (HDL) (Tall, Blum, & Grundy, 1983), which then can 
618 transport the PL to their target cells, tissues, and organs (Burri, Hoem, Banni, & Berge, 2012). 
619 Approximately 20% of the intestinal and dietary PL are passively absorbed intact and 
620 unaffected by digestive lipases, whereby they are incorporated into HDL (Lordan, Tsoupras, 
621 & Zabetakis, 2017). Notably, PL can also be integrated into pre-existing HDL particles in the 
622 intestine, which can subsequently join the plasma HDL pool (Burri, Hoem, Banni, & Berge, 
623 2012), thereby increasing the levels of intact PL absorbed into circulation capable of affecting 
624 platelet function and reactivity. The incorporation of intact PL into HDL particles may havehas 
625 important ramifications for cardiovascular pathology as individual HDL particles are thought 
626 to havepossess antithrombotic properties, which is attributed  to their PL membrane of the HDL 
627 particles (Camont, Lhomme, Rached, Le Goff, Nègre-Salvayre, Salvayre, et al., 2013). In light 
628 of these findings,Further studies investigating the incorporation of intact PL into plasma HDL  
629 are warranteds intensive investigation. Furthermore, studies studies that simulate 
630 gastrointestinal digestion, in vivo studies using enterocytes, and human postprandial studies 
631 are warranted to assess how effective thewhether the antithrombotic properties of dairy polar 
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637 The totality of the evidence indicates that ovine milk and yoghurt PL possess potent 
638 antithrombotic activity against PAF and thrombin and moderate biological activity against 
639 ADP-induced human platelet aggregation. C30RP-UHPLC-HRAM-MS/MS was employed to 
640 assess the effect of fermentation on the PL fraction of milk following fermentation by specific 
641 starter cultures. It was determined using multivariate statistical analysis that there was a 
642 significant difference in the PL composition in the yoghurts in contrast to the milk and that 
643 there were significant differences between the PL extracts of yoghurts A and B due to their 
644 differing starter cultures and the fermentation process. It is evident that these processes affect 
645 the antiplatelet properties of these yoghurts and that certain PL compositions are strongly 
646 inversely correlated with PAF- and thrombin-induced platelet aggregation. Notably, this study 
647 highlights that dietary sphingolipids and phospholipids such as SM, PE, and PC have the 
648 potential to affect platelet aggregation and warrant further intensive research in vivo. This 
649 research highlights that fermentation of milk can be altered to improve the antithrombotic 
650 properties of dairy PL.  further research is required to discern the exact metabolic pathways 
651 responsible for altering the PL content of milk in order to utilise these pathways for the 
652 production of tailored antithrombotic functional cardioprotective foods.
653
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837 Figure Legends
838 Fig. 1. (A) Chromatogram showing the of the C30RP-UHPLC-HRAM-MS/MS separation of 
839 the PL extracts in the negative ion mode. (B, C, and D) Representative LC-MS/MS mass 
840 spectra showing the fragmentation patterns of (B) PC(18:0/18:1), (C) PE(18:0/18:1), and (D) 
841 SM(16:0/18:1), which are all examples of molecular species that were identified in the three 
842 most abundant PL classes present in the milk and yoghurt. (E) The pie charts depict the relative 
843 abundance of the ovine milk, yoghurt A, and yoghurt B polar lipid (PL) extracts expressed as 
844 a nmol percentage of the total extracts. Abbreviations: PC, phosphatidylcholine; PE, 
845 phosphatidylethanolamine; PI, phosphatidylinositol; PS, phosphatidylserine; PL, polar lipids; 
846 SM, sphingomyelin
847
848 Fig. 2. Heat maps (2A, 2C, and 2E) demonstrating the variation between the most abundant PL 
849 lipid (PE, SM, and PC) molecular species present in ovine milk and yoghurts A and B. The 
850 various dairy sources and PL classes were clustered independently using ascendant hierarchical 
851 clustering based on Euclidian distance at 0.15 interquartile range. The left columns represent 
852 the segregation of the PL species, whereas the columns above segregate the milk and yoghurts 
853 based on similarities in abundance. Red, black, and green colours denote lower, intermediate, 
33
854 and higher abundance of the PL species. Group 1 and 2 (G1 and G2) and subgroups (SG1 and 
855 SG2) are the PL species that were responsible for the resulting clustered patterns in the heat 
856 maps that were used to determine statistical significance between the milk and yoghurt PL 
857 species in each of the bar charts (2B, 2D, and 2F) coupled to the heat maps. These bar charts 
858 report the relative abundance of the various molecular species of each lipid class as a mean 
859 nmol% ± SE (n = 4). Statistically significant differences between the lipid species are denoted 
860 by the letter A-C above the error bars as determined by Fisher’s LSD multiple comparisons 
861 test following ANOVA (α = 0.05). Group 1 and 2 (G1 and G2) and subgroups (SG1 and SG2) 
862 are the PL species that were responsible for the resulting clustered patterns in the heat maps 
863 that were used to determine statistical significance between the milk and yoghurt PL species 
864 as depicted in the bar charts. 
865
866 Fig. 3. Heat maps (3A and 3C) demonstrating the variation between PS and PI molecular 
867 species in ovine milk and yoghurts A and B. The various dairy sources and PL classes were 
868 clustered independently using ascendant hierarchical clustering based on Euclidian distance at 
869 0.15 interquartile range. The left columns represent the segregation of the PL species, whereas 
870 the columns above segregate the milk and yoghurts based on similarities in abundance. Red, 
871 black, and green colours denote lower, intermediate, and higher abundance of the PL species. 
872 Group 1 and 2 (G1 and G2) are the PL species that were responsible for the resulting clustered 
873 patterns in the heat maps that were used to determine statistical significance between the milk 
874 and yoghurt PI and PS species in each of the bar charts (3B and 3D) coupled to the heat maps. 
875 These bar charts report the relative abundance of the various molecular species of each lipid 
876 class as a mean nmol% ± SE (n = 4). Statistically significant differences between the lipid 
877 species are denoted by the letter A-C above the error bars as determined by Fisher’s LSD 
878 multiple comparisons test following ANOVA (α = 0.05). 
879 Fig. 4. Biplots showing the ovine milk and yogurt PL and molecular species associated with 
880 the IC50 values of the ADP, PAF, and thrombin platelet aggregation outputs derived from the 
881 PL extracts. A = PL biplot; B = PE biplot; C = SM biplot; D = PC biplot; E = PS biplot; F = PI 
882 biplot. The PCA analyses demonstrates that there tends to be a correlation between PAF and 
883 thrombin inhibition and the PL molecular species associated with yoghurt B in particular, 
884 which exhibited the most potent inhibitory effects against these two platelet agonists. However, 
885 no significant deduction can be made for ADP inhibition as none of the PL species tended to 
886 significantly cluster with ADP. Abbreviations: ADP, adenosine diphosphate; LPC, 
887 lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; LPS, lysophosphatidylserine; 
888 PA, phosphatidic acid; PAF, platelet-activating factor; PC, phosphatidylcholine; PE, 
889 phosphatidylethanolamine; PG, phosphatidylglycerol; PI, phosphatidylinositol; PL, polar 
890 lipids; PS, phosphatidylserine; SM, sphingomyelin; SPH, sphingosine
891
892 Fig. 5. Flow diagram showing the proposed pathways associated with the potential mechanisms 
893 of PAF and thrombin inhibition by dairy PL. (A) presents the heat map of the PL species of the 
894 milk and yoghurts that were significantly inversely correlated with inhibition of PAF and 
895 thrombin-induced platelet aggregation. It is clear from the heatmap that the majority of these 
896 proposed bioactive PL species were present in abundance in yoghurt B, which was the most 
897 bioactive yoghurt, but were present in less amounts in yoghurt A and in very low abundance in 
34
898 the milk. Image (B) is a schematic illustration of the most probable modes of action of these 
899 bioactive dairy PL against the PAF and thrombin pathways of platelet activation. In B1 and 
900 B2, PAF or PAFLL can bind to the PAF-R inducing platelet aggregation in platelets of 
901 inflammation related events in other cells. Structurally similar PL species can competitively 
902 bind the PAF-R preventing reducing platelet reactivity due to their lower potency. In B3 and 
903 B4, as some of the intact PL species are structurally homologous to the platelet membrane 
904 lipids they can be incorporated into the membrane. This leads to structural changes of the 
905 membrane surrounding the PAF-R for PAF or PAR-1 and PAR-4 for thrombin, which may 
906 impede the function of these receptors. Therefore, the biological activity of these receptors is 
907 reduced and their downstream effects are dampened or inhibited. This may be the same mode 
908 of action for ADP, however, further research is required. Image (C) is the a structural 
909 representation of PAF with its various critical features highlighted. It is postulated that dietary 
910 PL exert their effects on the PAF-R as depicted in B1 and B2 due to their structural similarities, 
911 i.e. hydrophilic head group, glycerol backbone, and fatty acid at the sn-1 position. 
912 Abbreviations: AA, arachidonic acid; ADP, adenosine diphosphate; cAMP, 3′–5′-cyclic 
913 adenosine monophosphate; cPLA2, cytosolic phospholipase A2; DAG, diacylglycerol; IP3, 
914 Inositol 1,4,5-triphosphate; LPCAT, lysophosphatidylcholine acyltransferase; PAF, platelet-
915 activating factor; PAFLL, PAF-like lipids; PAF-R; PAR, protease activated receptor; platelet-
916 activating factor receptor; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PI, 
917 phosphatidylinositol; PIP2, phosphatidylinositol 4,5-bisphosphate; PKA, protein kinase A; 
918 PKC, protein kinase C; PL, polar lipids; PLCβ, phospholipase C β; PS, phosphatidylserine; 





924 List of Tables: 
925
926 Table 1. Inhibition of adenosine diphosphate (ADP), platelet-activating factor (PAF), and 
927 thrombin induced platelet aggregation in human PRP by ovine milk and yoghurts total polar lipid 
928 extracts (TPL). 
929
Samples ADP PAF Thrombin
Milk 190.8 ± 72.4a 154.9 ± 13.2c 37.5 ± 5.2b
Yoghurt A 196.0 ± 79.2a   80.4 ± 10.2b 33.7 ± 6.4b
Yoghurt B 198.8 ± 78.0a 48.5 ± 5.7a 14.7 ± 6.0a
930 abc Mean values (n = 6), ± standard deviation with different letters in the same column indicating 
931 statistical significant differences when means are compared using the Kruskal Wallis test (p < 
932 0.05). The antithrombotic activity is denoted by the IC50 value (µg; mean ± SD). Abbreviations: 
35
933 adenosine diphosphate; IC50, 50% inhibitory concentration; PAF, platelet-activating factor; PRP, 
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